Compile Data Set for Download or QSAR
maximum 50k data
Found 55 Enz. Inhib. hit(s) with all data for entry = 10759
TargetUbiquitin carboxyl-terminal hydrolase 30 (USP30)(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565121((R)-3-((4-(4-chlorophenyl)piperidin-1- yl)sulfonyl...)
Affinity DataIC50: <100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30 (USP30)(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565120((S)-3-((4-(4-chlorophenyl)piperidin-1- yl)sulfonyl...)
Affinity DataIC50: <100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30 (USP30)(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565119(3-((4-(4-chlorophenyl)piperidin-1- yl)sulfonyl)pyr...)
Affinity DataIC50: <100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30 (USP30)(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565097(N-(1-cyanopyrrolidin-3- yl)-4-(pyrimidin-5- yl)ben...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30 (USP30)(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565125((R)-3-((3-(4-chlorophenyl)azetidin-1- yl)sulfonyl)...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30 (USP30)(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565124((S)-3-((3-(4-chlorophenyl)azetidin-1- yl)sulfonyl)...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30 (USP30)(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565123(3-((3-(4-chlorophenyl)azetidin-1- yl)sulfonyl)pyrr...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30 (USP30)(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565122(3-((4-benzylpiperidin-1- yl)sulfonyl)pyrrolidine-1...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30 (USP30)(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565117((3-((4-(pyridin-2-yl)piperazin-1- yl)sulfonyl)pyrr...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30 (USP30)(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565109(N-([1,1'-biphenyl]-4-yl)-1-cyanopyrrolidine- 3-sul...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30 (USP30)(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565108(N-(1-cyanopyrrolidin-3-yl)-N-methyl-4-((5-(trifluo...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30 (USP30)(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565107(N-(5-(N-(1-cyanopyrrolidin-3-yl)sulfamoyl)pyridin-...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30 (USP30)(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565115(US11414402, Example 23 | rac-(4aR,7aS)-4-(4-methyl...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30 (USP30)(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565113((3aR,6aR)-1-((4-(pyridin-3-yl)phenyl)sulfonyl)hexa...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30 (USP30)(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565106((R)—N-(1-cyanopyrrolidin-3-yl)-N-methyl-4-(pyridin...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30 (USP30)(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565105(N-(1-cyanopyrrolidin-3-yl)-4-((5- (trifluoromethyl...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30 (USP30)(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565103(N-(1-cyanopyrrolidin-3-yl)-6- phenoxypyridine-3-su...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30 (USP30)(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565102(N-(1-cyanopyrrolidin-3- yl)-4-(1-methyl-1H- pyrazo...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30 (USP30)(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565101(N-(1-cyanopyrrolidin-3- yl)-4-(piperidin-1- yl)ben...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30 (USP30)(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565100(N-(1-cyanopyrrolidin-3- yl)-4-(pyridin-4- yl)benze...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30 (USP30)(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565098(N-(1-cyanopyrrolidin-3- yl)-5-phenylpyridine-2- su...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30 (USP30)(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565096((4-(benzyloxy)-N-(1- cyanopyrrolidin-3- yl)benzene...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30 (USP30)(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565093((S)-N-(1-cyanopyrrolidin- 3-yl)-[1,1'-biphenyl]-4-...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30 (USP30)(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565092((R)-N-(1-cyanopyrrolidin- 3-yl)-[1,1'-biphenyl]-4-...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30 (USP30)(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565091(N-(1-cyanopyrrolidin-3- yl)-[1,1'-biphenyl]-4- sul...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30 (USP30)(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565090(N-(1-cyanopyrrolidin-3- yl)-[1,1'-biphenyl]-2- sul...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565105(N-(1-cyanopyrrolidin-3-yl)-4-((5- (trifluoromethyl...)
Affinity DataIC50:  550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565091(N-(1-cyanopyrrolidin-3- yl)-[1,1'-biphenyl]-4- sul...)
Affinity DataIC50:  5.50E+3nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565106((R)—N-(1-cyanopyrrolidin-3-yl)-N-methyl-4-(pyridin...)
Affinity DataIC50:  5.50E+3nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565096((4-(benzyloxy)-N-(1- cyanopyrrolidin-3- yl)benzene...)
Affinity DataIC50:  5.50E+3nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565097(N-(1-cyanopyrrolidin-3- yl)-4-(pyrimidin-5- yl)ben...)
Affinity DataIC50:  5.50E+3nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30 (USP30)(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565118(3-((4-(pyrimidin-2-yl)piperazin-1- yl)sulfonyl)pyr...)
Affinity DataIC50:  5.50E+3nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565099(N-(1-cyanopyrrolidin-3- yl)-4'-fluoro-[1,1'- biphe...)
Affinity DataIC50:  5.50E+3nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565100(N-(1-cyanopyrrolidin-3- yl)-4-(pyridin-4- yl)benze...)
Affinity DataIC50:  5.50E+3nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30 (USP30)(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565112(N-(1-cyanopyrrolidin-3-yl)-5-fluoro-2- methylbenze...)
Affinity DataIC50:  5.50E+3nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565102(N-(1-cyanopyrrolidin-3- yl)-4-(1-methyl-1H- pyrazo...)
Affinity DataIC50:  5.50E+3nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30 (USP30)(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565104(N-(1-cyanopyrrolidin-3-yl)-4- isopropylbenzenesulf...)
Affinity DataIC50:  5.50E+3nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30 (USP30)(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM50418001(CHEMBL1672421 | US11414402, Example 6)
Affinity DataIC50:  5.50E+3nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30 (USP30)(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM50417989(CHEMBL1672422 | US11414402, Example 7)
Affinity DataIC50:  5.50E+3nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565108(N-(1-cyanopyrrolidin-3-yl)-N-methyl-4-((5-(trifluo...)
Affinity DataIC50:  5.50E+3nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565093((S)-N-(1-cyanopyrrolidin- 3-yl)-[1,1'-biphenyl]-4-...)
Affinity DataIC50:  5.50E+3nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30 (USP30)(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565111(N-(1-cyanopyrrolidin-3- yl)-4-(4- methylpiperazin-...)
Affinity DataIC50:  5.50E+3nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM50095489(CHEMBL275080 | N-(1-Cyano-pyrrolidin-3-yl)-benzene...)
Affinity DataIC50:  5.50E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM50418001(CHEMBL1672421 | US11414402, Example 6)
Affinity DataIC50:  5.50E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565098(N-(1-cyanopyrrolidin-3- yl)-5-phenylpyridine-2- su...)
Affinity DataIC50:  5.50E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565101(N-(1-cyanopyrrolidin-3- yl)-4-(piperidin-1- yl)ben...)
Affinity DataIC50:  5.50E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565103(N-(1-cyanopyrrolidin-3-yl)-6- phenoxypyridine-3-su...)
Affinity DataIC50:  5.50E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565104(N-(1-cyanopyrrolidin-3-yl)-4- isopropylbenzenesulf...)
Affinity DataIC50:  5.50E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase 30 (USP30)(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565114(US11414402, Example 22 | rac-(4aR,7aR)-4-tosylhexa...)
Affinity DataIC50:  5.50E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Homo sapiens (Human))
Mission Therapeutics

US Patent
LigandPNGBDBM565109(N-([1,1'-biphenyl]-4-yl)-1-cyanopyrrolidine- 3-sul...)
Affinity DataIC50:  5.50E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 55 total ) | Next | Last >>
Jump to: